Clinical Trial Update: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types [Phase 2]

View source ↗

Summary

Phase 2 trial update indicating access to pembrolizumab for selected rare cancer types has been secured.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma Neuroendocrine
• Central Nervous System Neoplasm
• Neoplasms Germ Cell and Embryonal
• Nk T-cell Lymphoma
• Ovarian Neoplasm
• Sarcoma
• Thyroid Neoplasm

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: UNICANCER | Conditions: Sarcoma, Ovarian Neoplasm | Phase 2 | Status: COMPLETED